Tigapotide
Tigapotide (PCK-3145) is an anti-tumour peptide that reduces the development of skeletal metastases associated with prostate cancer. Tigapotide induces apoptosis and reduces tumour parathyroid hormone-related peptide (PTHrP) levels[1].
Product Specifications
CAS Number
848084-83-3
Product Name Alternative
PCK-3145
UNSPSC
12352209
Target
Apoptosis
Type
Peptides
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/tigapotide.html
Solubility
10 mM in DMSO
Smiles
OC(C=C1)=CC=C1C[C@@H](C(N[C@@H](CCC(O)=O)C(N[C@H](C(O)=O)[C@H](O)C)=O)=O)NC([C@H](CSCNC(C)=O)NC([C@H]([C@H](O)C)NC([C@H](CSCNC(C)=O)NC([C@H]([C@H](O)C)NC([C@H](CCC(O)=O)NC([C@H](CSCNC(C)=O)NC([C@H](CC(N)=O)NC([C@H](CC(O)=O)NC([C@H]([C@H](O)C)NC([C@H](CCC(N)=O)NC([C@@H](NC([C@@H](N)CCC(O)=O)=O)CC2=CNC3=CC=CC=C23)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O
Molecular Formula
C82H119N21O34S3
Molecular Weight
2039.14
References & Citations
[1]Pippa N, et al. Advanced nanocarriers for an antitumor peptide. Journal of nanoparticle research, 2013, 15 (11) : 1-13.
Shipping Conditions
Room temperature
Scientific Category
Peptides
Clinical Information
Phase 1
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
